India: Indian Patent Office Rejects Bayer’s Tosylate Salt Form Of Drug Sorafenib

On 24th February 2015, the Indian Patent office refused Bayer Healthcare AG'S attempt to patent tosylate salt form of its anticancer drug Sorafenib, known under the brand name Nexavar. The application had earlier been opposed through 2 pre-grant oppositions – by generic pharmaceutical company NATCO and as well as by Fresenius Kabi Oncology Ltd1.

FACTS OF THE CASE

Bayer Healthcare filed an application for patent with application number 1960/DELNP/2007 IN Delhi Patent office on March 14, 2007 entitled "THERMODYNAMICALLY STABLE FORM OF A TOSYLATE SALT". The Applicant amended the set of claims in reply to FER on 4th March, 2014. Subsequently two pre-grant oppositions were filed against this application, first one by NATCO Pharma Limited, Hyderabad and second one by Fresenius Kabi Oncology Limited, Gurgaon.

GROUNDS OF OPPOSITION FILED BY NATCO

Ground I: Section 3(c): Claims 1-18 drawn to polymorphic forms of 4-{4-[({[4-chloro-3-trifluoromethyl) phenyl] amino} carbonyl) amino] phenoxy}-N-methyl pyridine-2- carboxamide also known as Sorafenib is a known compound from WO 00/42012, WO 03/068228 and WO 03/047579.

Section 3(d): Claims 1-18 drawn to polymorphic forms of 4-{4-[({[4-chloro-3-trifluoromethyl) phenyl] amino} carbonyl) amino] phenoxy}-N-methyl pyridine-2- carboxamide also known as Sorafenib is a known compound. The alleged invention of polymorphic form I, as claimed, is not supported by any examples or any other data of enhanced efficacy over that of known substances, including the metastable form. Moreover the process for the preparation of Sorafenib tosylate polymorph I as claimed in claims 2-4 neither involve any new reactant nor result in any new product. Thus the claimed invention falls within the scope and mischief of Section 3 (d).

Section 3(e): Claims 7, 8 and 12 and 15-18 are drawn to a pharmaceutical compositions, the composition comprises of the polymorphs of claims 1 along with a pharmaceutically acceptable excipient. But as there are no examples to shoe their synergism, the composition is called a mere admixture.

Section 3(i): Claims 5-6 and 9-11 correspond to method of treatment and are not patentable under sec 3(i).

Ground II: Section 25(1) (b)/(c): None of the claims of 1960/DELNP/2007 are novel.

Ground III: Section 25(1)(e) Lack of inventive step

1. The conversion of one polymorphic form to another polymorphic form is well known in prior art.

2. The use of the inert solvent and seeding technology for the conversion one polymorphic form to another polymorphic form is known from the prior art.

Hence, the process of conversion of polymorphs and the resultant polymorphic form is well known from prior art.

Ground IV: Section 25(1)(f), 2(1)(ja): The invention is devoid of inventive step.

Ground V: Section 25(1)(g): Complete specification of 1960/DELNP/2007 does not describe the invention claimed or the method by it is performed.

Ground VI: Section 25(1)(h): The applicant has failed to furnish the details of National Phase applications filed in USA, Europe, etc which are still under examination and not granted.

GROUNDS OF OPPOSITION FILED BY FRESENIUS KABI ONCOLOGY LTD

Section 25(1)(b) Novelty/Anticipation: The invention so far claimed in any claimed of the complete specification has been published before the priority date of the claim.

Section 25(1)(d) Prior Knowledge/Prior Use: That the invention so far as claimed in any claim of the complete specification was publicly known or publicly used in India before the priority date of that claim.

Section 25(1)(e) Obviousness/Lack of inventive step: That the invention so far as claimed in any claim of the complete specification is obvious and clearly does not involve any inventive step, having regard to the matter published as mentioned in clause (b) or having regard to what was used in India before the priority date of the applicant's claim.

Section 25(f) Not Patentable subject matter: That the subject of any claim of the complete specification is not an invention within the meaning of this Act, or is not patentable under this Act.

Section 25(1) Insufficient Disclosure: That the complete specification does not sufficiently and clearly describe the invention or the method by which it is to be performed.

APPLICANT'S ARGUMENTS

Bayer Healthcare refuted all the grounds of oppositions raised by both the opponent companies. The Applicant argued that the polymorphic form I of the tosylate salt of Sorafenib as claimed in the present application is not disclosed in any of the earlier cited documents by the Opponents. It also further submitted that the complete specification of the patent application sufficiently and clearly described the invention as well as the method by which it is to be performed and the opponent's objection on this ground as well should be rejected out rightly.

CONTROLLER'S DECISION

Ground I (Section 3(C)): With regards to this ground the Assistant Controller concluded that the document WO 00/42012 relates Sorafenib base & does not describe any polymorphic form of sorafenib tosylate salt. Though the documents WO 03/047579 and WO 03/068228 describe a tosylate salt of sorafenib but as such there is no mention of any polymorphic form. Therefore, this ground is not validly established by Opponent. Further, the polymorphic forms of Sorafenib tosylate are sufficiently and clearly described in the description in the tables 2 to 6 by X-Diffractometry, IR Spectroscopy, Raman Spectroscopy and NIR Spectroscopy. Hence the ground II (Section 25(1) (g)) Insufficient Disclosure is not validly established by the Opponents.

With regards to Section 3(e) the Controller concluded that the claims of the present lack inventive step on the basis of cited documents, the combination or composition claims does not have any relevance and are not patentable under Section 3(e) of the Patents Act 1970. The Controller further acknowledged that the present invention is novel as the document WO 00/42012 does not describe any polymorphic form of sorafenib tosylate salt. WO 03/068228 and WO 03/047579 describe a tosylate salt of sorafenib but without any specification of the polymorphic form. Further, none of the prior art mentioned the use of any polymorphic form of sorafenib tosylate, nor does any concrete evidence provided by the opponent for prior use of the polymorphic form I of sorafenib tosylate. Therefore, the grounds of opposition under section 25(1) (d) (Prior use) were not validated by the Controller.

INVENTIVE STEP

The Applicant had mentioned in their arguments that there is a need to find the most stable form of a compound because only the most stable form can ensure that all properties and characteristics regarding stability, dissolution rate, shelf life, efficacy and bioavailability remain constant during manufacturing, storage and administration. The applicant addresses the problem by providing a polymorphic form I of sorafenib tosylate which is surprisingly more stable than the other polymorphs found and ensures a constant and reliable efficacy, therapeutic or otherwise. The Controller had pointed that combining the teachings of the cited documents of the prior art for a skilled artisan, it is a clear cut motivation to prepare stable polymorphic form of sorafenib tosylate as claimed in the impugned patent with enhanced properties with reasonable success by combing the teachings of the references as mentioned in the cited documents no inventive step resides in the same. For the contentions raised by Fresenius Kabi Oncology Ltd, the Controller stated that stirring or shaking and seeding technology is very well known in prior art can be used top prepare a thermodynamically stable polymorph. By combing the teachings of the annexed documents, a skilled artisan could practically arrive at a process of converting one polymorph to another using the already mentioned solvents in the prior art. Thus the Controller concluded that claims of the present invention lacked inventive merit.

With regards to Section 3(d), the Controller opined that the invention failed to demonstrate therapeutic efficacy and therefore fails to fulfill the requirement of patentable invention u/s 3(d) of the patents Act. Further, the Controller noted that the Applicant has creatively attempted to escape liability by furnishing the required details at the last moment and filing a petition for obviation for delay. Therefore, in the present case the Applicant has failed to comply with the provisions of Section 8(1) of the Patents Act.

CONCLUSION:

After considering the representation and expert evidence of opponents, reply of the Applicant, expert evidence in support of the applicant, written submissions and arguments in the hearing made by both the parties, the Controller refused the application 1960/DELNP/2007 on the ground of lack of inventive step (Section 2(1)(ja), Section 3(d),Section 3(e) and Section 25(1)(h) of the Patents Act, 1970.

Footnote

1. http://ipindiaservices.gov.in/decision/1960-DELNP-2007-9548/1960%20order.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions